Mapping the genetic basis of breast microcalcifications and their role in metastasis

Asif Rizwan1, Santosh Kumar Paidi2, Chao Zheng2,3, Menglin Cheng1, Ishan Barman2,4 & Kristine Glunde1,4,5

Breast cancer screening and early stage diagnosis is typically performed by X-ray mammography, which detects microcalcifications. Despite being one of the most reliable features of nonpalpable breast cancer, the processes by which these microcalcifications form are understudied and largely unknown.

In the current work, we have investigated the genetic drivers for the formation of microcalcifications in breast cancer cell lines, and have investigated their involvement in disease progression. We have shown that stable silencing of the Osteopontin (OPN) gene decreased the formation of hydroxyapatite in MDA-MB-231 breast cancer cells in response to osteogenic cocktail. In addition, OPN silencing reduced breast cancer cell migration. Furthermore, breast cancer cells that had spontaneously metastasized to the lungs in a mouse model of breast cancer had largely elevated OPN levels, while circulating tumor cells in the same mouse model contained intermediately increased OPN levels as compared to parental cells. The observed dual roles of the OPN gene reveal the existence of a direct relationship between calcium deposition and the ability of breast cancer cells to metastasize to distant organs, mediated by common genetic factors.

Breast cancer is the most common malignancy in women with an incidence rate of about 120 in 100,000 women in the United States1. The 5 year survival rate of breast cancer patients drops from ~99% for Stage I patients, to ~27% for Stage IV disease, and thus necessitates early detection1. Mammography to reveal microcalcifications in the breasts is the most widely used tool in breast cancer screening and for the initial diagnosis of non-palpable breast tumors2. The use of microcalcifications as a reliable biomarker of breast cancer has also been questioned due to their association with both benign and malignant lesions, which leads to unnecessary biopsies3,4. Specifically, microcalcifications that are composed of calcium hydroxyapatite are found in both benign breast lesions and breast cancers whereas those constituted by calcium oxalate crystals are largely indicative of benign lesions. For several decades, research has mostly focused on recognizing the various morphologies that microcalcifications can have in breast tissue and their correlation with the degree of malignancy5. Emerging evidence from us and others suggests that higher hydroxyapatite content in mammary microcalcifications is a marker for malignant disease whereas lower hydroxyapatite and a relatively higher calcium carbonate content is characteristic of benign breast lesions6. Yet, such studies have provided limited information about the mechanisms governing the genesis of microcalcifications and their role in disease progression.

After having collectively been viewed as a result of cellular degeneration, a paradigm shift has recently been proposed that specific type(s) of microcalcifications are products of active cellular processes and may result from processes similar to those involved in physiological bone mineralization7,8. Bellahacene et al. reported increased expression of bone matrix proteins, which are typically involved in physiological bone mineralization, in human breast cancer cells, and speculated that they may have a role in hydroxyapatite formation9,10. Recently, Scimeca et al. showed that, under specific stimuli, epithelial cells undergoing epithelial-mesenchymal-transition (EMT)
transform themselves into cells with an osteoblast-like phenotype, and are able to contribute to the production of breast microcalcifications\textsuperscript{11}. They further demonstrated that the localization of hydroxyapatite in these cancer cells was similar to that in osteoblasts. These observations suggest that to understand the role of microcalcifications in breast cancer, it is imperative to systematically explore the genetic basis of their formation, subsequent transportation into the extracellular matrix and involvement in metastatic cancer progression.

In the current study, we seek to identify and study key genetic factors that guide the formation of microcalcifications from mammary cells, and their relationship with the migration capabilities of human breast cancer cells. To achieve this, we have examined publicly available microarray data sets for potential gene candidates in a blinded and unbiased fashion, which are differentially expressed in aggressive human breast cancer cell lines that typically develop microcalcifications \textit{in vitro} compared to non-aggressive lines. The obtained list of candidate genes was further refined by selecting genes encoding proteins that have putative roles in tissue or cellular microcalcification. We identified the SPP1 gene encoding osteopontin (OPN) to be the most differentially expressed gene characteristic of aggressive cell lines in our list of genes. Osteopontin (OPN) is a secreted soluble glycoprotein that is present in most body fluids including milk and serum\textsuperscript{13}. It is overexpressed in a number of different carcinomas and has previously been implicated as an enhancer of mineralization in human breast cancer samples\textsuperscript{8}. Secreted OPN interacts with multiple cell surface receptors, including various integrins (integrin β1, integrin β3) and CD44\textsuperscript{14,15}. Several studies have proposed a link between OPN and cancer\textsuperscript{16–20}. This link, in particular to metastasis, is based on the binding of OPN to cell surface receptors such as CD44, which is critical to EMT initiation and cell-matrix adhesion in various types of primary tumors\textsuperscript{11–13}.

Through shRNA knockdown of OPN in human MDA-MB-231 breast cancer cells, we have shown a direct involvement of the OPN gene in the formation of microcalcifications. Moreover, OPN knockdown resulted in reduced migration in \textit{in vitro} assays, which was mediated at least in part by reduced CD44. The contribution of OPN to the migratory properties of the cancer cells was validated through \textit{in vivo} studies by quantifying and comparing levels of OPN and CD44 expression in parental MDA-MB-231 cells orthotopically implanted in the mouse, MDA-MB-231 cells that have escaped from the primary tumor into the blood circulation, and MDA-MB-231 cells that have successfully metastasized to the lungs.

**Results**

**Osteopontin expression increases with breast cancer cell aggressiveness and osteogenic cocktail treatment.** We used the GEO dataset GSE16795, which contains gene expression profiles of 39 human breast cancer cell lines, and divided it into two groups of five metastatic and five non-metastatic with high relevance to our experimental work\textsuperscript{24}. Among the genes that are differentially expressed in metastatic versus non-metastatic cell lines, the genes encoding proteins with putative roles in the context of breast microcalcifications are shown in Fig. 1A in decreasing order of their log two-fold change. Figure 1A also shows the differential expression of the listed genes across the cell lines in the dataset as a heat map. Specifically, gene expression levels of OPN were found to be significantly (p-value = 0.0047) elevated (~29 fold) for the metastatic group compared to the non-metastatic group. We analyzed the protein–protein interactions of significantly differentially expressed genes in the selected metastatic versus non-metastatic cell lines from GSE16795 using the STRING-10.5 (http://string-db.org) analysis software and database\textsuperscript{25}. Figure 1B visualizes a subset of the identified biological processes and pathways that involve OPN (SPP1). Network nodes are colored by pathway membership, and pathways are sorted by increasing false discovery rate. Pathways that were most significantly activated, i.e. cell migration, extracellular matrix organization, tissue development, and chemotaxis, were also circled in the same color as the corresponding nodes. Additional pathways with significant activation in metastatic cells that involve OPN were response to extracellular stimulus, regulation of response to external stimulus, cell adhesion, regulation of cell differentiation, and focal adhesion. Solid and dotted lines represent intra-cluster and inter-cluster functional associations, respectively. As seen from Fig. 1B, OPN (SPP1) directly interacts with CD44 and FGF2, which in turn interact with several other proteins, including vimentin (VIM) through CD44.

As the next step, we cultured metastatic (MDA-MB-231 and SUM-149) and non-metastatic (BT-474 and T47D) human breast cancer cell lines and characterized their OPN mRNA expression levels as determined by qRT-PCR. To assess the relationship between calcification status and OPN expression level, the same cell lines were cultured in media enriched with osteogenic cocktail for induction of microcalcifications. Figure 2A shows the OPN mRNA expression results in the presence of osteogenic cocktail. The OPN mRNA expression levels of cells cultured in the absence of osteogenic cocktail are shown alongside for comparison. The OPN mRNA expression levels are significantly higher in both of the metastatic as compared to both of the non-metastatic breast cancer cell lines. It is also evident that OPN expression increases substantially with the addition of exogenous phosphates in the form of osteogenic cocktail, indicating that OPN may play a crucial role in mediating the formation of microcalcifications in breast cancer cells. The metastatic triple-negative human breast cancer cell line MDA-MB-231 was employed as the model system for further investigations in this study.

**Stable shRNA silencing of OPN inhibits the formation of cellular microcalcifications.** To study the role of the OPN gene (SPP1) in the formation of microcalcifications in MDA-MB-231 cells, stable clones were generated using shRNA knockdown of the SPP1 gene in these cells. Four stable clones - shOPN1 through shOPN4 - were identified, characterized, and used for further studies. Figure 2B shows significantly reduced OPN mRNA expression levels in the stably OPN silenced lines versus empty-vector control cells, confirming sufficient shRNA gene knockdown. Stably silenced clones and control cells were sub-cultured in the presence of osteogenic cocktail for 7 days to induce the formation of microcalcifications. The cells were fixed and stained with alizarin red S to selectively report for the presence of microcalcifications. Figure 3A shows representative images of stably OPN silenced MDA-MB-231 clones and control cells stained with alizarin red for qualitative comparison. Three independent batches of cells were stained and the average calcification content of the cells is
shown in Fig. 3B along with standard deviations. Our observations reveal that there is a consistent inhibition of the formation of cellular microcalcifications due to OPN gene silencing in the knockdown clones. The similarity in the trend of variation in level of OPN mRNA expression and cellular calcification content across the knockdown clones further strengthens our hypothesis that the OPN gene positively regulates the formation of cellular microcalcifications.

Stable OPN silencing reduces the migration of aggressive MDA-MB-231 cells. The impact of stable OPN silencing on the migration of MDA-MB-231 cells was tested using transwell migration assays. All four stably OPN silenced MDA-MB-231 lines employed in the study, shOPN1 through shOPN4, displayed reduced cell migration compared to control cells. Figure 4 shows representative migration assay images along with the quantitative comparison of migration ability for all the clones studied. The differences in migration ability were statistically significant for all clones when compared to control cells, and consistent for all the biological repeats (n = 3).

Over-expression of OPN in circulating tumor cells (CTC) and lung metastatic cells (LMC). Motivated by the reduction of migration capabilities of the cells in the in vitro experiments, we performed orthotopic inoculations of MDA-MB-231 breast cancer cells and derived MDA-MB-231 tumor cells from the blood

Figure 1. (A) Expression profiles of genes relevant to breast microcalcifications that are differentially expressed in metastatic and non-metastatic breast cancer cell lines. The gene expression heat map focused on genes directly linked to microcalcifications was obtained by subjecting the publicly available microarray dataset GSE16795 to the Gene-e matrix visualization and analysis platform. From the 38 cell lines included in the dataset, 5 non-metastatic and 5 metastatic cell lines with high relevance to our experimental work were identified and utilized to generate the heat map. (B) Protein-protein interaction network of differentially expressed genes in the selected metastatic versus non-metastatic cell lines. Identified biological processes and pathways that involve OPN (SPP1) are shown. Network nodes are colored by pathway membership, and pathways are sorted by increasing false discovery rate. Interactions are colored by type of interaction as listed in the legend. Solid and dotted lines represent intra-cluster and inter-cluster functional associations, respectively.
circulation (circulating tumor cells, CTC) and lungs (lung metastatic cells, LMC) at 8–12 weeks following inoculation as shown in Fig. 5A. These CTC and LMC were examined to verify the relevance of our findings in vivo.

Figure 5B shows the mean and standard deviation of OPN mRNA expression levels comparatively for parental MDA-MB-231 cells, CTC, and LMC. The observations reveal 80-fold and 160-fold increased expression of OPN in CTC and LMC, respectively, as compared to the parental MDA-MB-231 cells. We also tested the expression levels of two of the genes identified as interacting with OPN in our protein-protein interaction analysis (Fig. 1B), which are involved in cell migration, extracellular matrix organization, and cell adhesion. The means and standard deviations of CD44 mRNA (Fig. 5C) and VIM mRNA (Fig. 5D) expression levels are shown comparatively for parental MDA-MB-231 cells, CTCs, and LMCs. We observed significant decreases in CD44 mRNA expression in CTCs and LMCs as compared to parental MDA-MB-231 cells. VIM mRNA expression was significantly increased in CTCs and LMCs. Differences in CD44 and VIM mRNA levels between CTCs and LMCs were not significantly different.

Discussion
Cellular mechanisms driving the formation of mammary microcalcifications in breast cancer cells remain unclear despite their extensive use in breast cancer screening and staging. Since the molecular biology of the formation of microcalcifications in breast cancer is poorly understood, we performed an initial in silico screen using an existing mRNA database for comparing highly metastatic breast cancer cell lines with non-metastatic breast cancer cell
Figure 4. Silencing of OPN gene results in reduction of in vitro migration potential of the knockdown clones. (A) Representative bright-field images showing crystal violet stained membranes of transwell inserts for the four stably silenced clones and vector control. The scale bars represent 200 µm. (B) Bar plot showing mean and standard deviation of number of migrated cells for stably silenced clones as percentage of vector control. Conventional Student t test threshold (p < 0.05) was considered statistically significant and is indicated by *.

Figure 5. In vivo migration of MDA-MB-231 cells is dependent on expression of osteopontin. (A) Schematic of in vivo study conducted to isolate fluorescent tumor cells of varying metastatic potential from blood and metastatic lungs of mice carrying orthotopic MDA-MB-231 xenograft. Bar plots showing mean and standard deviation of (B) OPN mRNA, (C) CD44 mRNA, and (D) VIM mRNA expression for circulating tumor cells (CTCs) and lung metastatic cells (LMCs) relative to parental MDA-MB-231 cells. Conventional Student t test threshold (p < 0.05) was considered statistically significant and is indicated by *.
lines. In this screen, we selectively considered genes with a putative direct or indirect relationship with breast microcalcifications or bio-mineralization in general. Osteopontin, the protein encoded by the gene SPP1, which had the highest differential expression in our analysis, has previously been associated with both physiological and pathological mineralization in various organs, making it a good candidate gene for further investigation. The increased expression of this gene in MDA-MB-231 cells in response to osteogenic cocktail treatment further supported the possibility of its involvement in inducing mammary mineralization. The osteogenic cocktail we used is known to induce intracellular mineralization comprising of calcium hydroxyapatite due to the increased availability of phosphate in the cell culture media with addition of β-glycerophosphate, and therefore has emerged as a popular in vitro model for studying mineralization.

The significant suppression of intracellular mineralization as assessed by alizarin red S staining of cells cultured in osteogenic cocktail in stably OPN silenced MDA-MB-231 cells suggests that OPN is one of the principal factors directly governing cellular mineralization processes in triple-negative breast cancer cells. Studies in the past have shown that OPN is critical for both promotion and inhibition of hydroxyapatite formation in normal bone and connective tissue cells. More recently, it has been reported that the regulation of hydroxyapatite formation depends on the phosphorylation state of OPN and its interactions with other molecules such as osteocalcin. OPN also has been reported to act as hydroxyapatite nucleator when present in certain suitable conformations. Based on this evidence and the results presented in this study, we reason that the formation of microcalcifications in breast cancer cells is a result of the availability of OPN in its phosphorylated state, and its dynamic interaction with several other proteins. Our observation that OPN regulates the formation of microcalcifications in breast cancer cells is in agreement with recent observations by Scimeca et al. that mammary microcalcifications are found in breast epithelial cells that have developed an osteoblast-like phenotype. Such osteoblast-like cells developed from breast epithelial progenitors by the enforced expressions of mesenchymal characteristics. The osteoblast-like phenotype was sustained by bone morphogenic protein-2 (BMP-2), and these cells exhibited localized hydroxyapatite-rich cytoplasmic vesicles similar to hydroxyapatite containing intracellular vesicles found in osteoblasts. In the same study, increased focal expression of OPN was observed in the proximity of hydroxyapatite, which was also a characteristic feature of lesions in biopsied tissues, showing microcalcifications along with increased mesenchymal markers such as VIM. This observation is consistent with significantly increased expression levels of the genes encoding OPN and VIM in our microarray analysis as well as in our animal model of spontaneous dissemination, in which CTCs and LMCs concurrently displayed elevated levels of OPN and VIM as compared to parental human MDA-MB-231 breast cancer cells. Together, our results support the notion that microcalcifications in aggressive breast cancer cells are driven by processes similar to those governing physiological mineralization.

Furthermore, the relationship between the microcalcification status of breast cancer cells and their metastatic capabilities remains largely unexplored. In our microarray analysis of publicly available data, we observed that OPN was significantly involved and interacted with cell migration, extracellular matrix organization, chemotaxis, and cell adhesion in metastatic breast cancer cells. Motivated by these data and the finding that microcalcifications are preferentially produced in cells displaying a mesenchymal phenotype, we assessed the effect of stable OPN knockdown on the migration capabilities of MDA-MB-231 cells. The significant inhibition of migration that we detected in all knockdown clones in in vitro transwell migration assays indicates that OPN expression directly affects the migration abilities of breast cancer cells. Our results are in good agreement with a recent study by Zhang et al., in which OPN knockdown in breast cancer cells resulted in integrin-induced inhibition of cell migration and invasion, and promoted apoptosis through induction of autophagy and inactivation of PI3K/Akt/mTOR pathway. Our data also agree with recently published data showing that transient siRNA knockdown of OPN in murine mammary tumor cell lines reduced cell migration.

From an orthotopic mouse xenograft model of spontaneous metastasis in vivo, we observed that the OPN mRNA expression level from MDA-MB-231 cells that had spontaneously metastasized to the lungs (LMC) were significantly higher than that from circulating tumor cells (CTC) from the same model, which in turn were significantly higher than that in parental cells. These progressively increasing OPN levels in MDA-MB-231 cells of the same genetic background, which have progressively traveled farther down the metastatic cascade confirms in an in vivo system of spontaneous metastasis that dramatically increased OPN levels are most likely required for MDA-MB-231 cells to metastasize. These observations further suggest that the OPN gene is expressed differentially in the same aggressive breast cancer cell type depending on where these cancer cells are in their metastatic journey.

Concurrently, we observed progressively decreased expression levels of CD44, which were highest in parental MDA-MB-231 cells, significantly decreased in CTCs, and the most dramatically decreased in LMCs. CD44 is a cell surface glycoprotein involved in cell communication and adhesion between adjacent cells and between cells and the extracellular matrix. Reduced CD44 expression levels were previously shown to enhance breast cancer metastasis, which is in good agreement with our observations. Our studies thus provide further proof for an interaction between OPN and CD44 that helps aggressive breast cancer cells to facilitate migration, spontaneous dissemination, and formation of metastatic nodules.

We also observed that the expression of VIM was significantly enhanced in CTCs and LMCs as compared to parental MDA-MB-231 cells. VIM is an intermediate filament protein that induces changes in the shape and motility of cells that are undergoing EMT. Triple-negative breast cancers were previously shown to display elevated VIM expression levels compared to other types of breast tumors. High expression levels of VIM in primary breast cancers were reported to support the formation of metastases in distant organs. Taken together, our observations reinforce that an OPN-CD44-VIM interaction axis with implications in inducing EMT and reducing adhesion, helped triple-negative MDA-MB-231 cells to disseminate and form distant metastases.

Due to its active role in the regulation of several key pathways that have implications in disease progression, OPN is emerging as a novel therapeutic target. The findings of the current study may enable accurate
monitoring of response to such therapy through the evaluation of changes in microcalcification status. In addition, by exploring the relationship between OPN therapy and its impact on metastatic progression, changing microcalcification status can potentially be utilized as a marker to track metastatic development.

In conclusion, two major findings suggest the possibility of a fundamental relationship between mammary microcalcifications and metastatic capabilities of the cells in which they are formed. These findings are: (i) breast lesions rich in hydroxyapatite-based microcalcifications are associated with poor prognosis, and (ii) evidence presented here that OPN is positively regulating both cellular microcalcification as well as breast cancer cell migration and metastasis, which may occur through the observed OPN-CR44-VIM axis. Future studies further exploring the causal molecular relationship between microcalcifications and metastasis in breast cancer are important for a comprehensive understanding of microcalcification etiology and their improved use as diagnostic and prognostic marker in breast cancer.

**Materials and Methods**

**Identification of candidate genes responsible for breast microcalcifications.** The publicly available breast cancer microarray dataset GSE 16795 was analyzed where multiple breast cancer cell lines were grown to optimal cell densities for mRNA extraction and hybridization on Affymetrix microarrays. A heat map was generated using the Gene-e matrix visualization and analysis platform (http://www.broadinstitute.org). This heat map represents changes in relative content of mineralization-related gene expression levels in 5 metastatic breast cancer cell lines (MDA-MB-231, MDA-MB-435s, SK-Br-7, SUM102PT, SUM149PT) and 5 non-metastatic breast cancer cell lines (BT-474, BT-483, MCF7, MDA-MB-415, T47D).

**Protein–protein interaction network.** The prominent genes overexpressed in the selected metastatic cell lines in the Gene-e analysis were employed to visualize protein–protein interactions using the STRING-10.5 (http://string-db.org) computational tool and database with a high confidence interval of 0.7. The STRING network, composed of the functional protein associations is based on genomic context, high-throughput experiments, co-expression, and scientific reports. Functional enrichments in the network were identified using the STRING tool, and a subset of the identified biological processes and pathways that involve OPN (SPP1) were selected for visualization. The nodes in the network are colored according to their membership in each of the identified pathways and the pathways are sorted in the legend by increasing false discovery rates.

**Cell culture.** The human breast cancer cell lines MDA-MB-231, SUM 149, BT-474 and T47D were obtained from the American Type Culture Collection (ATCC, MD). All cell lines were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 µg/ml fungizone antimycotic (Life Technology, Grand Island, NY, USA) and maintained in a humidified incubator in 5% CO₂ at 37 °C. In a subset of the studies, the cell culture media was supplemented with an osteogenic cocktail containing 10 mM 3-glycerophosphate (Sigma-Aldrich) and 50 mg/ml¹ ascorbic acid (Sigma-Aldrich) for promoting the formation of microcalcifications.

**Generation of stably OPN silenced breast cancer cell lines.** MDA-MB-231 cells were transfected with lentiviral particles expressing shRNA against human OPN (sc-36129-V, Santa Cruz Biotechnology, Dallas, Texas) to specifically knockdown the expression of the human OPN gene. These OPN shRNA lentiviral particles were purchased as a pool of concentrated, transduction-ready viral particles containing 3 target-specific constructs that encode 19–25 nt (plus hairpin) shRNA designed to knock down OPN gene expression. Stably transduced clones were developed, along with a vector control cell line expressing a control shRNA lentiviral particle (sc-108080, Santa Cruz Biotechnology). qRT-PCR to measure OPN mRNA and immunoblotting of OPN confirmed successful transduction. For stably expressing lines, transfected cells were passaged and maintained in media containing Puromycin dihydrochloride (sc-108071, Santa Cruz Biotechnology). Cells were kept under selection for 7–10 days. Then, the cells from the selection step were plated at a density of 10 cells per ml in a 96-well tissue culture plate by adding 100 µl per well (i.e., 1 cell per well). Selected single-colony wells in the 96-well tissue culture plate were expanded to high confluence and transferred to a 24-well tissue culture plate. Once the colonies in 24-well tissue culture plates were expanded to high confluence, they were passaged to a 6-well tissue culture plate. Clonal cell lines were assessed by qRT-PCR to select lines with significantly decreased levels of OPN gene expression.

**qRT-PCR.** Three cell lines from each group (MDA-MB-231, CTC, LM) were analyzed for gene expression with two technical repeats and two biological repeats each. For RNA purification, cells were grown for 48 hours in exponential growth phase and mRNA was isolated and purified using the RNeasy total RNA isolation kit (Qiagen, Germantown, MD) according to the manufacturer’s protocol. mRNA was reverse transcribed into cDNA using qScript™ cDNA SuperMix (Quanta Bioscience, Gaithersburg, MD) according to the manufacturer’s protocol. mRNA was reverse transcribed into cDNA using qScript™ cDNA SuperMix (Quanta Bioscience, Gaithersburg, MD) according to the manufacturer’s protocol. Quantitative real-time PCR (q-RT-PCR) was performed using IQ SYBR Green Supermix and gene-specific primers in the iCycler RT-PCR detection system (Bio-Rad, Hercules, CA) with 2 µl of diluted cDNA samples (1:10) used as a template using the following primers. The sequences for forward and reverse primers for quantifying SPP1 mRNA, which expresses the OPN protein, were 5′-CGAGGTGTAGTGTGGTATATG-3′ and 5′-CAGGCGCATGAGAAGTATC-3′, respectively. The sequences for forward and reverse primers for quantifying CD44 mRNA were 5′-CGGACACCATGGAAGATGTTT-3′ and 5′-GAAAGCTCTGAGGAGGCTG-3′, respectively. The sequences for forward and reverse primers for quantifying VIM mRNA were 5′-GCAAAATGCTTGGTCG-3′ and 5′-GACATGACAGAGAGATG-3′, respectively. The housekeeping gene Hypoxanthinephoribosyltransferase-1 (HPRT1) was used as internal reference gene for quantification as previously described. The expression of RNA relative to HPRT1 was calculated based on the Ct as R = 2^-△Ct, where △Ct = Ct_target – Ct_HPRT, mRNA gene expression level was reported as mean ± standard deviation.
Alizarin Red S staining and quantification of mineralization. The cell monolayers were fixed using 4% formaldehyde after washing gently with PBS. Alizarin red S staining solution at pH 4.1–4.3 was added to the fixed cell monolayers and incubated in the dark for 45 min. Cell monolayers were carefully washed with distilled water and PBS after aspirating the remaining alizarin red S solution. The stained cells were imaged using a camera (Lumenera Infinity 1) mounted on a microscope (Leica DMLB, 0.4 NA and 20 × magnification objective). Several images of the stained cells were captured from three independent cultures for each stable clone, (each frame capturing more than 50 cells) and the pixels corresponding to alizarin red were quantified and normalized to the total number of cells per frame to remove the effects of any differences in cell densities across the clones. The pixels corresponding to the alizarin red stained areas were identified by their RGB decomposition obtained using MATLAB (Mathworks, Natick, MA) and the cells in each frame were counted using the manual mode of Image-J software. The colors determined by the criterion R > 180, R > G + 80 and B < 100 were found to accurately represent the color of the alizarin red S stain.

In Vitro migration assays. Transwell inserts (Costar) with porous polycarbonate membranes with a pore size of 8 μm were used to measure the effect of stable OPN silencing on migration in MDA-MB-231 cells. shRNA constructs of size of 88 bp were used to create stable transfections. Stable transfectants were selected using constitutive puromycin resistance in the presence of 2 μg/ml puromycin. When the stable transfectant exhibited > 80% puromycin resistance in the presence of 2 μg/ml puromycin, it was considered to be stable. The resulting tissue suspension was then passed twice through a 20 G syringe needle to completely disperse the remaining tissue. Two weeks after cell culture of CTC and LMC, the tdTomato-expressing CTC or LMC cells were sorted by FACS to clear out all non-fluorescent non-cancer cells of lung origin.

Experimental animal models: Generation of CTC and LMC. All animal experiments were approved by the Johns Hopkins University Animal Care and Use Program in compliance with the Animal Welfare Act regulations and Public Health Service (PHS) policy. Johns Hopkins University has an approved PHS Assurance and maintains accreditation of our program by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. MDA-MB-231 cells were stably transfected with a construct containing DNA of tdTomato fluorescent protein as previously described. Stably tdTomato-expressing MDA-MB-231 breast cancer cells (2 × 10⁶) were orthotopically implanted into the fourth right mammary fat pad of 6 weeks old female athymic nu/nu female mouse (NCI) as described previously. When primary tumor volume reached approximately 500 mm³ after about 8–12 weeks following inoculation, the mouse was sacrificed, its blood was obtained by cardiac puncture, and its lungs were collected to isolate and culture CTC and LMC, respectively, as briefly described in the following. For CTC isolation, cardiac puncture yielded about 500 μl of blood from each mouse. Red blood cells were lysed (ACK lysing buffer, Life technology, Grand Island, NY, USA) and CTCs were pelleted by centrifugation, suspended in RPMI 1640 culture medium, and CTCs were pelleted by centrifugation, suspended in RPMI 1640 culture medium, and CTC presence was verified by fluorescence microscopy of tdTomato-expression in MDA-MB-231 cells. For LMC isolation, both lungs were carefully macerated in 0.25% trypsin/EDTA solution. Lung tissue was digested at 37 °C for 1 hour to maximize trypsin penetration. Warm, complete media was added to the tissue pieces, which was gently dispersed by pipetting. The resulting tissue suspension was then passed twice through a 20 G syringe needle to completely disperse any remaining tissue. Two weeks after cell culture of CTC and LMC, the tdTomato-expressing CTC or LMC cells were sorted by FACS to clear out all non-fluorescent non-cancer cells of lung origin.

Quantification and statistical analysis. Statistical significance of the differences between quantitative measurements were analyzed by unpaired two-tailed Student’s t-test. P-values < 0.05 were considered to be statistically significant.

References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68, 7–30 (2018).
2. Gulsün, M., Demirkazık, F. B. & Arıyürek, M. Evaluation of breast microcalcifications according to breast imaging reporting and data system criteria and Le Gal’s classification. European Journal of Radiology 47, 227–231 (2003).
3. Evans, A. J., Wilson, A. R. M., Burrell, H. C., Ellis, I. O. & Pinder, S. E. Morphometric features of ductal carcinoma in situ (DCIS) present on previous mammography. Clinical Radiology 54, 644–646 (1999).
4. Johnson, J. M., Dalton, R. R., Wester, S. M., Landercasper, J. & Lambert, P. J. Histological correlation of microcalcifications in breast biopsy specimens. Archives of Surgery 134, 712–716 (1999).
5. Morgan, M., Cooke, M. & McCarthy, G. Microcalcifications Associated with Breast Cancer: An Epiphrenomenon or Biologically Significant Feature of Selected Tumors? J Mammary Gland Biol Neoplasia 10, 181–187 (2005).
6. Sathyavathi, R. et al. Raman spectroscopic sensing of carbonate intercalation in breast microcalcifications at stereotactic biopsy. Sci Rep 5, 9907 (2015).
7. Kirsch, T. Determinants of pathological mineralization. Current Opinion in Rheumatology 18, 174–180 (2006).
8. Shroff, R. C. & Shanahan, C. M. Vascular Calcification in Patients with Kidney Disease: The Vascular Biology of Calcification. Seminars in Dialysis 20, 103–109 (2007).
9. Bellahcene, A. & Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. The American journal of pathology 146, 95–100 (1995).
10. Bellahcene, A., Merville, M. P. & Castronovo, V. Expression of Bone Sialoprotein, a Bone Matrix Protein, in Human Breast Cancer. Cancer Research 54, 2823–2826 (1994).
11. Scimeca, M. et al. Microcalcifications in breast cancer: an active phenomenon mediated by epithelial cells with mesenchymal characteristics. BMC Cancer 14, 286 (2014).
12. Senger, D. R., Perruzzi, C. A., Papadopoulos, A. & Tenen, D. G. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica et biophysica acta 996, 43–48 (1989).
13. Wang, K. X. & Denhardt, D. T. Osteopontin: role in immune regulation and stress responses. *Cytokine & growth factor reviews* **19**, 333–345 (2008).

14. Senger, D. R., Wirth, D. F. & Hynes, R. O. Transformed mammalian cells secrete specific proteins and phosphoproteins. *Cell* **16**, 885–893 (1979).

15. Gardner, H., Berse, B. & Senger, D. R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 Ehrhoblasts. *Oncogene* **9**, 2321–2326 (1994).

16. Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T. & Chambers, A. F. Reduced Malignancy of ras-transformed NIH 3T3 Cells Expressing Antisense Osteopontin RNA. *Cancer Research* **54**, 832 (1994).

17. Singhal, H. et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. *Clinical Cancer Research* **3**, 605–611 (1997).

18. Rodrigues, L. R., Teixeira, J. A., Schmitt, F. L., Paulsson, M. & Lindmark-Mansson, H. The role of osteopontin in tumor progression and metastasis in breast cancer. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* **16**, 1087–1097 (2007).

19. Li, N. Y. et al. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. *Journal of the American College of Surgeons* **217**, 17–26; discussion 26 (2013).

20. Zhu, Y. et al. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. *Science cancer* **(2017).”

21. Weber, G. F., Ashkar, S., Glimecher, M. J. & Cantor, H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). *Science* **271**, 509–512 (1996).

22. Ahmed, M. et al. Osteopontin/CD44 axis in RhoGDI2-mediated metastasis suppression. *Cancer cell* **30**, 432–443 (2016).

23. Katagiri, Y. U. et al. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. *Cancer Research* **59**, 219–226 (1999).

24. Hollestelle, A. et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. *Breast Cancer Res Treat* **121**, 53–64 (2009).

25. Szklarczyk, D. et al. STRINGv10: protein–protein interaction networks, integrated over the tree of life. *Nucleic Acids Research* **43**, D447–D452 (2015).

26. Cox, R. F. et al. Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. *Br J Cancer* **106**, 525–537 (2012).

27. Boskey, A. L. et al. Osteopontin- hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin–gel. *Bone and Mineral* **22**, 147–159 (1993).

28. McKee, M. D. & Nanci, A. Osteopontin: An Interfacial Extracellular Matrix Protein in Mineralized Tissues. *Connective Tissue Research* **35**, 197–205 (1996).

29. Gericke, A. et al. Importance of Phosphorylation for Osteopontin Regulation of Breas. *Calcified tissue international* **77**, 45–54 (2005).

30. Zhang, H. et al. Osteopontin Knockdown Inhibits αv/33 Integrin-Induced Cell Migration and Immunization and Promotes Apoptosis of Breast Cancer Cells by Inducing Autoptoly and Inactivating the PI3K/Akt/mTOR Pathway. *Cellular Physiology and Biochemistry* **33**, 991–1002 (2014).

31. Saleh, S., Thompson, D. E., McConkey, J., Murray, P. & Moorehead, R. A. Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. *BMC Cancer* **16**, 359 (2016).

32. Zoller, M. CD44 can a cancer-initiating cell profit from an abundantly expressed molecule? *Nature Reviews Cancer* **11**, 254 (2011).

33. Lopez, J. et al. CD44 Attenuates Metastatic Invasion during Breast Cancer Progression. *Cancer Research* **65**, 6755 (2005).

34. Mendez, M. G., Kojima, S.-I. & Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. *The FASEB Journal* **24**, 1838–1851 (2010).

35. Takeyama, Y. et al. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. *Cancer Letters* **296**, 216–220 (2014).

36. Karishita, P. et al. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. *Breast Cancer Research and Treatment* **138**, 81–90 (2013).

37. Alix-Panabieres, C. & Pantel, K. Challenges in circulating tumor cell research. *Nature Reviews Cancer* **14**, 623 (2014).

38. Bandopadhyay, M. et al. Osteopontin as a therapeutic target for cancer. *Expert Opin Ther Targets* **18**, 883–895 (2014).

39. Tuck, A. B., Chambers, A. F. & Allan, A. L. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. *Cytokine & growth factor reviews* **20**, 515–527 (2013).

40. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer cell* **10**, 515–527 (2006).

41. de Kok, J. B. et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. *Laboratory investigation; a journal of technical methods and pathology* **85**, 154–159 (2005).

42. Riswan, A. et al. Metastatic breast cancer cells in lymph nodes increase nodal collagen density. *Sci Rep* **5**, 10002 (2015).

43. Riswan, A. et al. Breast cancer cell adhesion and degradation interact to drive metastasis. *Nat Breast Cancer* **1**, 15017 (2015).

44. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. *Nature protocols* **3**, 1101–1108 (2008).

45. Schneider, C. A., Rasband, W. S. & Elsonr, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat Meth* **9**, 671–675 (2012).

46. Riswan, A. et al. Relationships between LDH-A, Lactate and Metastases in 4T1 Breast Tumors. *Clin Cancer Res* **19**, 5158–5169 (2013).

**Acknowledgements**

A.R., M.C. and K.G. acknowledge the support of National Cancer Institute grants R01 CA154725, R01 CA213428, and R01 CA213492. S.K.P. and I.B. acknowledge the JHU Whiting School of Engineering Startup Funding as well as support from National Institute of Biomedical Imaging and Bioengineering (2-P41-EBO15871-31) and National Institute of General Medical Sciences (grant no. DP2GM128198). C.Z. acknowledges the support of the National Natural Science Foundation of China NSFC Grant No. 81702603. We acknowledge Dr. Zaver M. Bhujwalla (Johns Hopkins Medicine) and Dr. Balaji Krishnamachary (Johns Hopkins Medicine) for helpful discussions.

**Author Contributions**

A.R., S.K.P., C.Z., I.B. and K.G. designed research; A.R., S.K.P., C.Z. and M.C. performed experiments, A.R., S.K.P., C.Z. and M.C. analyzed data, and A.R., S.K.P., C.Z., I.B. and K.G. wrote the manuscript. Figure 5A was drawn by A.R. All authors discussed the results and reviewed the manuscript.
Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018